EUVIMEDEUVIMED entdecken
Crossref

Design, synthesis and antitumor activity evaluation of novel modified 18β-glycyrrhetinate derivatives as PPARγ agonists

Hongyan Lin, Shuaijun Cui, Xinye Xu, Qingqing Chen, Jiazi Ge, Dongxuan Ai, Jie Zhu, Yuheng Tao, Liqun Wang, Lingyu Ruan, Wenhao Ge

Bioorganic Chemistry · 2025

DOI: 10.1016/j.bioorg.2025.108307 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2025. Verfasst von Hongyan Lin und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy and School of Biological and Food Engineering, Changzhou University, Changzhou, Jiangsu 213164, China. Hauptthemen laut MEDLINE: PPAR gamma, Glycyrrhetinic Acid, Drug Design, Cell Proliferation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Jiangsu Province Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

18β-Glycyrrhetinic acid (18β-GA) is the main active component of licorice and one of the most promising lead compounds in traditional Chinese herbal medicine. Previous studies have shown that 18β-GA can act as a PPARγ agonist to exert antitumor activity. However, the number of reported 18β-GA derivatives as PPARγ agonists is limited and they have significant toxic side effects, which greatly restricts their application and development. To obtain highly effective and low-toxic PPARγ agonists, through structure-activity relationship (SAR) analysis, we constructed a molecular library of 18β-GA derivatives containing 13,440 compounds and screened out 14 novel 18β-GA ester derivatives. The selected compounds were evaluated for their antitumor activity in vitro. The results showed that most of the compounds exhibited strong anti-proliferative activity against five human cancer cell lines, especially the human colon cancer cell line HT-29, without significant toxicity to normal cell lines. Among them, C1 had the strongest anti-proliferative activity against HT-29, with an IC50 value of 12.25 μM, which was 12 times higher than that of its parent nucleus 18β-GA. C1 can block the cell cycle of HT-29 cells in G2/M phase, significantly inhibit their migration and induce their apoptosis. Molecular docking and dynamics simulation results suggested that C1 could stably bind to the active pocket of PPARγ. Further PPARγ activity analysis and drug-likeness prediction results indicated that C1 could act as a PPARγ agonist to exert antitumor effects and had certain drug-likeness, which is worthy of further study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PPAR gammaGlycyrrhetinic AcidDrug DesignCell ProliferationAntineoplastic AgentsDrug Screening Assays, AntitumorDose-Response Relationship, DrugHumansStructure-Activity RelationshipMolecular StructureApoptosisMolecular Docking SimulationCell Line, Tumor

Stichwörter der Autor:innen

18β-Glycyrrhetinic acidAntitumor activityMolecular dockingPPARγ activationStructure activity relationship

Substanzen

PPAR gammaGlycyrrhetinic AcidAntineoplastic Agents18alpha-glycyrrhetinic acid

Autor:innen und Institutionen

  • School of Pharmacy and School of Biological and Food Engineering, Changzhou University, Changzhou, Jiangsu 213164, China.
  • State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210023, China.
  • School of Pharmacy and School of Biological and Food Engineering, Changzhou University, Changzhou, Jiangsu 213164, China. Electronic address: ruanlingyu@cczu.edu.cn.
  • Changzhou Second People's Hospital, Changzhou Medical Center, Nanjing Medical University, Jiangsu 213100, China. Electronic address: 15062215991@163.com.

Förderung

  • National Natural Science Foundation of China
  • Jiangsu Province Natural Science Foundation

Zitieren

APA

Lin, H., Cui, S., Xu, X., Chen, Q., Ge, J., Ai, D., Zhu, J., Tao, Y., Wang, L., Ruan, L., & Ge, W. (2025). Design, synthesis and antitumor activity evaluation of novel modified 18β-glycyrrhetinate derivatives as PPARγ agonists. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2025.108307

Vancouver

Lin H, Cui S, Xu X, Chen Q, Ge J, Ai D, et al. Design, synthesis and antitumor activity evaluation of novel modified 18β-glycyrrhetinate derivatives as PPARγ agonists. Bioorganic Chemistry. 2025. doi:10.1016/j.bioorg.2025.108307

BibTeX
@article{Lin2025,
  author = {Lin, Hongyan and Cui, Shuaijun and Xu, Xinye and Chen, Qingqing and Ge, Jiazi and Ai, Dongxuan and Zhu, Jie and Tao, Yuheng and Wang, Liqun and Ruan, Lingyu and Ge, Wenhao},
  title = {Design, synthesis and antitumor activity evaluation of novel modified 18β-glycyrrhetinate derivatives as PPARγ agonists},
  journal = {Bioorganic Chemistry},
  year = {2025},
  doi = {10.1016/j.bioorg.2025.108307}
}
Kostenlos starten →